منابع مشابه
[Extreme thrombocytopenia following abciximab therapy].
Antagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 patients (74% men) who underwent percutaneous ...
متن کاملAbciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
A 62-year-old man with a history of coronary artery disease and coronary artery bypass graft, chronic heart failure, and peripheral vascular disease required percutaneous coronary intervention (PCI) after progression of shortness of breath and fatigue over 2 years. Four hours after the procedure, the patient developed hematemesis and was found to be thrombocytopenic. The thrombocytopenia was pr...
متن کاملUnderstanding the complexity of abciximab-related thrombocytopenia.
Patients with a rare bleeding disorder characterised by skin and mucosal bleeding – typical of thrombocytopenia – but with a normal platelet count, and later characterised by a defective aggregation to all agonists, described as Glanzmann thrombasthenia, have mutations in a platelet membrane glycoprotein (GP) called GP IIb/IIIa, also known as the integrin αIIbβ3 (1). Such discovery paved the ro...
متن کاملFurther complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia.
674 Acute thrombocytopenias are common clinical problems of diverse etiologies and paradoxically, some of the most dramatic forms are iatrogenic in nature (1). For example, drugs that are given to patients to treat or prevent arterial or venous thrombosis (such as heparin, abciximab, and other agents that block the platelet integrin receptor αIIbβ3) can cause immune reactions that lead to life-...
متن کاملSunitinib Induced Immune Thrombocytopenia
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: QJM
سال: 2002
ISSN: 1460-2393
DOI: 10.1093/qjmed/95.9.635